Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03787498 · ClinicalTrials.gov registry record · Phase 1
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
A Phase 1 study of Relapsed Acute Myeloid Leukemia (AML) and Refractory Acute Myeloid Leukemia (AML), sponsored by Opna Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 6
- Study locations
NCT03787498: Completed Phase 1 study of Relapsed Acute Myeloid Leukemia (AML) and Refractory Acute Myeloid Leukemia (AML), sponsored by Opna Bio.
NCT03787498 is a Phase 1 study of Relapsed Acute Myeloid Leukemia (AML) and Refractory Acute Myeloid Leukemia (AML) that has completed, run by Opna Bio. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03787498, a Phase 1 study of Relapsed Acute Myeloid Leukemia (AML) and Refractory Acute Myeloid Leukemia (AML), has completed, sponsored by Opna Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Conditions Studied
Interventions
- DRUG PLX2853
Study Locations (6)
Georgia
- Northside Hospital - Atlanta
Maryland
- Sidney Kimmel Comprehensive Cancer At Johns Hopkins - Baltimore
New York
- NewYork-Presbyterian / Weill Cornell Medical Center - New York
Ohio
- Ohio State University Medical Center - Columbus
Oregon
- Oregon Health and Sciences University - Portland
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-03-19 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 1 |
What the finished NCT03787498 record still lists
NCT03787498 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).
The record links to 3 conditions, with Relapsed Acute Myeloid Leukemia (AML) appearing as the primary indexed condition, and to 1 intervention - of which PLX2853 is the first listed.
NCT03787498 lists 6 locations in 6 states (Georgia, Maryland, New York).
Frequently Asked Questions
What is clinical trial NCT03787498 about?
NCT03787498 is a clinical study titled "A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome". The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
What is the current status of trial NCT03787498?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2019-03-19. Estimated completion is 2021-06-30.
What conditions does trial NCT03787498 study?
This clinical trial studies the following conditions: Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS).
What interventions are being tested in trial NCT03787498?
The interventions under investigation include: PLX2853 (DRUG).
Who is sponsoring clinical trial NCT03787498?
This trial is sponsored by Opna Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03787498 being conducted?
This trial has 6 study locations across Georgia, Maryland, New York, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed Acute Myeloid Leukemia (AML)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03787498's enrollment target sits among peer trials
22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI